Ryan Cole examines Casgevy, the world's first approved CRISPR medicine for sickle cell disease and beta thalassemia. While revolutionary, delivering this autologous gene therapy faces massive challenges: a $2.2 million price tag, months-long manufacturing, only 50 global treatment centers, and access barriers in regions with highest disease burden.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI
続きを読む
一部表示